A 62-year-old woman from Mumbai presents with postmenopausal bleeding and is found to have endometrial cancer on biopsy. Staging MRI shows a 4 cm tumor with deep myometrial invasion (>50%) and loss of the junctional zone. The cervix appears uninvolved. She is medically fit for surgery. Staging laparotomy reveals a stage IIA tumor (cervical stromal invasion) with no positive pelvic or para-aortic lymph nodes (pN0). Histology is grade 2 endometrioid adenocarcinoma. What is the most appropriate adjuvant treatment?

Explanation

## Clinical Context and Staging This patient has **stage IIA endometrial cancer** (cervical stromal invasion without endocervical glandular involvement) with grade 2 endometrioid histology and negative lymph nodes. Deep myometrial invasion (>50%) combined with cervical stromal invasion places her in the **high-intermediate to high-risk category**. ## Risk Stratification in Endometrial Cancer | Risk Category | Features | Adjuvant Treatment | |---------------|----------|--------------------| | Low risk | Stage IA, grade 1–2, endometrioid, no LVSI | Observation | | Intermediate risk | Stage IB, grade 1–2, endometrioid; OR any grade 3 stage IA–IB | VBT ± chemotherapy | | High-intermediate risk | Age >60 + 2 of: grade 2–3, LVSI, outer third myometrial invasion | VBT or EBRT | | High risk | Stage IIA–IIB, grade 3, non-endometrioid, LVSI, positive nodes | Chemotherapy + radiation | **Key Point:** Stage IIA (cervical stromal invasion) is classified as **high-risk disease** and requires multimodal adjuvant therapy combining chemotherapy and radiation. ## Adjuvant Treatment Algorithm for Stage IIA ```mermaid flowchart TD A[Stage IIA endometrial cancer]:::outcome --> B{Lymph node status}:::decision B -->|pN0| C[High-risk disease]:::outcome B -->|pN1/pN2| D[Very high-risk disease]:::outcome C --> E{Grade and histology}:::decision E -->|Grade 1-2, endometrioid| F[Chemotherapy + Pelvic EBRT]:::action E -->|Grade 3 or non-endometrioid| G[Chemotherapy + Extended field EBRT]:::action D --> H[Chemotherapy + Extended field EBRT]:::action F --> I[Improved recurrence-free survival]:::outcome G --> I H --> I ``` **High-Yield:** The combination of chemotherapy (typically carboplatin-paclitaxel) and pelvic external beam radiation therapy (EBRT) is the standard adjuvant approach for stage IIA endometrial cancer with negative lymph nodes. This regimen reduces both locoregional and distant recurrence. **Clinical Pearl:** Cervical stromal invasion (stage IIA) carries a significantly higher risk of pelvic nodal metastases (~15–20%) and distant recurrence compared to stage IB disease, justifying the addition of systemic chemotherapy to locoregional radiation. ## Rationale for Combined Chemotherapy + EBRT 1. **Locoregional control:** EBRT addresses the increased risk of pelvic recurrence from cervical involvement 2. **Systemic control:** Chemotherapy targets occult micrometastatic disease 3. **Evidence base:** Combined-modality therapy improves recurrence-free survival in stage IIA disease compared to radiation alone 4. **Histology consideration:** Grade 2 endometrioid is still intermediate-grade; combined therapy is justified **Mnemonic:** **CHEMO-EBRT** = Chemotherapy + External Beam Radiation Therapy (the gold standard for stage IIA endometrial cancer). [cite:Park 26e Ch 16; NCCN Endometrial Cancer Guidelines 2023]